The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
This webpage serves as notice under 35 U.S.C. §287(a) that the following products are protected by one or more U.S. patents. Each product also may be covered by one or more foreign patents, and additional patent application(s) may be pending.
The following list of products and U.S. patents may not be all inclusive, and other products not listed here may be protected by one or more patents.
|Covered by one or more of the following U.S. patents: 7909790, 9039652, 9149613, 10252037 and 11235131
|Covered by one or more of the following U.S. patents: 10898631, 10918778, 11559618
|Covered by one or more of the following U.S. patents: 9956336, 10569003, 11464891, 11602583